바이러스 벡터 CTDMO 서비스

외부 리소스

• An Effective Analytical Testing Strategy for Viral Vectors Should Include these 7 Steps

  In this article, we provide our recommendations for designing a phase-appropriate analytical strategy can help ensure viral vector therapies meet regulatory requirements and industry standards.

• The Key to Viral Vector Success: A Seamless Experience from Development to Manufacturing

  Discover how our multidisciplinary and collaborative approach to viral vector development and manufacturing enables successful outcomes for our customers’ cell and gene therapies.

• Development Strategies for Adenovirus-based Gene Therapies

  In this case study, we outline the challenges of scaling up viral vector production, and how we were able to support our customer’s therapeutic through our platform approach.

• Are You Using Next-Gen Sequencing to Inform AAV Product and Process Quality? Here are 4 Reasons You Should

  Learn more about how next-gen sequencing provides critical insights to streamline and accelerate AAV gene therapies to patients.

• Balancing Phase-Appropriate Needs with Commercial Readiness in Viral Vector Manufacturing

  Discover how partnering with a trusted and experienced viral vector CDMO can help unlock unique insights to support your cell and gene therapy development.

• Addressing Manufacturing Challenges in Gene Therapy Development

  Learn how our Manufacturability Assessment can help identify and address development and manufacturing challenges when bringing new therapies to market.

• 5 Ways Experience Matters in Gene Therapy Manufacturing

  Discover how partnering experienced viral vector CTDMO can help guide you through the complexities of manufacturing and overcome regulatory hurdles to bring new therapies to patients.

• Automation in Analytics: Streamlining & Enhancing Gene Therapy Production

  In this white paper, learn why is important to establish an analytics program in early clinical development, and how partnering with an experienced CDMO that can establish an data-driven, streamlined analytics approach is key in accelerating program development.

• An Optimized & Streamlined Approach for Upstream & Downstream Lentiviral Production

  Watch the video and read the poster to learn how we optimized our VirusExpress^® platform for lentiviral vectors to maximize titers, enrich recovery, and reduce time to GMP manufacturing.

• Applying High Throughput Processes to Optimize AAV Titers

  In this article, we explore how establishing an innovative DoE approach helped optimize the transfection and scale up of an AAV-based gene therapy.